Sensus Healthcare (NASDAQ:SRTS) Issues Quarterly Earnings Results

Posted by Teresa Graham on Feb 6th, 2025

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01), Zacks reports. Sensus Healthcare had a net margin of 22.54% and a return on equity of 17.99%.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock traded down $2.73 during trading hours on Thursday, hitting $6.26. The company had a trading volume of 1,539,660 shares, compared to its average volume of 313,849. Sensus Healthcare has a twelve month low of $2.91 and a twelve month high of $9.33. The company has a market cap of $102.60 million, a P/E ratio of 10.95 and a beta of 1.24. The company’s 50-day moving average is $7.49 and its two-hundred day moving average is $6.89.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Maxim Group increased their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. HC Wainwright lifted their price objective on Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, November 18th. Finally, Lake Street Capital began coverage on shares of Sensus Healthcare in a report on Friday, January 31st. They set a “buy” rating and a $18.00 target price on the stock.

Check Out Our Latest Stock Report on Sensus Healthcare

About Sensus Healthcare

(Get Free Report)

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.